Orphazyme not seeking fresh capital despite reduced cash position
After receiving a rejection from the US FDA on Friday, Orphazyme has shaved DKK 300m off its annual cash flow guidance. CEO rejects having plans to chase fresh capital.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY NIELSINE NIELSEN
Although Orphazyme will be missing out on a considerable amount of money after its application to the US Food and Drug Administration (FDA) was rejected on Friday, the CEO Christophe Bourdon tells MedWatch that he does not predict that the firm will be seeking extra funds in a capital hunt.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
